Viatris VTRS Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Developed Markets Segment | $2.03B+6.7% | $2.26B+4.8% | $2.27B-1.8% | $2.13B-8.4% | $1.9B-12.6% | |
| Emerging Markets Segment | $537.4M+2.7% | $565.8M+10.1% | $571.8M+6.8% | $556.9M-4.4% | $523.1M-16.8% | |
| Greater China | $680.1M+22.4% | $572.9M+9.7% | $615.2M+9.4% | $588.9M+9.2% | $555.5M+2.1% | |
| Japan, Australia and New Zealand Segment | $273.5M-1.3% | $306.6M-8.8% | $307.3M-11.1% | $306.7M-12.3% | $277.1M-12.9% | |
| Operating Income (Loss) by Business | ||||||
| Developed Markets Segment | $780.8M+5.8% | —— | $944.1M-9.4% | $875.5M-13.1% | $738.1M-19.2% | |
| Emerging Markets Segment | $246.7M+4.5% | —— | $233.6M+12.2% | $238.1M+2.3% | $236M-15.6% | |
| Greater China | $497.3M+29.3% | —— | $416.8M+15.1% | $401.8M+15.0% | $384.7M+5.0% | |
| Japan, Australia and New Zealand Segment | $64.7M+4.0% | —— | $70.2M-31.8% | $83.7M-17.4% | $62.2M-28.8% | |
| Charges by Business | ||||||
| Corporate Segment and Other Operating Segment | $4.2M— | —— | —— | —— | —— | |
| Developed Markets Segment | $67.5M— | —— | —— | —— | —— | |
| Emerging Markets Segment | $5.7M— | —— | —— | —— | —— | |
| Greater China | $500K— | —— | —— | —— | —— | |
| Selling, general and administration by Business | ||||||
| Developed Markets Segment | $232.8M-0.6% | $255.1M-6.8% | $229M-7.7% | $249.5M-14.6% | $234.3M-17.2% | |
| Emerging Markets Segment | $71.1M-4.3% | $83.7M+19.9% | $73.6M-5.8% | $78.4M+0.5% | $74.3M-11.5% | |
| Greater China | $111.9M+1.7% | $144.6M+5.9% | $133M-1.3% | $124.6M-4.7% | $110M-5.5% | |
| Japan, Australia and New Zealand Segment | $34.4M-10.4% | $41.3M-9.4% | $37.9M-5.5% | $41.3M+0.2% | $38.4M-7.2% | |
| Cost of Sales by Business | ||||||
| Developed Markets Segment | $1.01B+9.3% | —— | $1.09B+7.3% | $1B-2.0% | $926.2M-5.1% | |
| Emerging Markets Segment | $219.6M+3.2% | —— | $264.6M+6.3% | $240.4M-11.5% | $212.8M-19.8% | |
| Greater China | $70.9M+16.6% | $61.9M+3.2% | $65.4M+0.2% | $62.5M+5.6% | $60.8M-0.7% | |
| Japan, Australia and New Zealand Segment | $174.4M-1.2% | —— | $199.2M-1.6% | $181.7M-12.3% | $176.5M-6.8% | |
| Foreign currency translation by Business | ||||||
| Developed Markets Segment | -$62.8M-125% | $19.8M+105% | $0-100% | $277M+1,126% | $250.3M+263% | |
| Emerging Markets Segment | -$1.7M-122% | —— | —— | $4.7M+143% | $7.8M+204% | |
| Greater China | $2.2M+22.2% | $4.2M+139% | $1.2M— | $4.5M+381% | $1.8M+124% | |
| Japan, Australia and New Zealand Segment | $0-100% | —— | —— | —— | $5.7M+123% | |
| Goodwill, Impaired, Accumulated Impairment Loss by Business | ||||||
| Developed Markets Segment | $3.19B0.0% | $3.19B+243% | $3.19B+243% | $3.19B+243% | $3.19B+243% | |
| Emerging Markets Segment | $499M0.0% | $499M+502% | $499M+302% | $499M+302% | $499M+302% | |
| Japan, Australia and New Zealand Segment | $651.8M0.0% | $651.8M+85.7% | $651.8M+85.7% | $651.8M+85.7% | $651.8M+2,073% | |
| Goodwill by Business | ||||||
| Developed Markets Segment | $4.96B+4.6% | $5.02B-25.6% | $5B-29.9% | $5.02B-27.7% | $4.74B-32.0% | |
| Emerging Markets Segment | $795.3M-0.2% | $797M-31.5% | $797.1M-32.4% | $801.3M-31.1% | $796.6M-32.1% | |
| Greater China | $935.4M+1.3% | $933.2M+1.3% | $929M-0.4% | $927.8M+0.4% | $923.3M-0.2% | |
| Japan, Australia and New Zealand Segment | $0— | $0-100% | $0-100% | $0-100% | $0-100% | |
| Net Sales by Product | ||||||
| Brands | $2.33B+10.2% | $2.35B+8.3% | $2.44B+3.2% | $2.28B-3.3% | $2.12B-8.3% | |
| Celebrex ® | $67.1M+5.8% | $66.2M-1.3% | $73.3M-1.1% | $70M-3.0% | $63.4M-12.2% | |
| Creon ® | $97.4M+18.2% | $98.9M+9.4% | $93.1M+10.0% | $91.4M+16.9% | $82.4M+9.9% | |
| Dymista ® | $37.3M-12.9% | $38.6M-6.5% | $33.8M-22.3% | $48.4M-12.0% | $42.8M-11.2% | |
| Effexor ® | $62M+4.6% | $68.1M+5.6% | $67.2M+1.4% | $63.1M+0.6% | $59.3M-0.2% | |
| EpiPen® Auto-Injectors | $101.1M+4.6% | $79M+8.1% | $157.2M+27.6% | $136.8M+18.4% | $96.7M+20.6% | |
| Generics | $1.18B+4.5% | $1.34B-0.3% | $1.31B-4.7% | $1.28B-9.7% | $1.13B-16.2% | |
| Lipitor | $462M+19.1% | $377.3M+6.0% | $396.1M+5.5% | $387.9M+11.3% | $388M-0.2% | |
| Lyrica ® | $120.6M+7.1% | $119.8M-5.7% | $126.5M-2.6% | $128.1M+3.1% | $112.6M-1.4% | |
| Norvasc | $210M+21.9% | $175.2M+5.4% | $179.7M+6.4% | $182.7M+12.8% | $172.3M-2.3% | |
| Viagra ® | $95M-3.6% | $104.2M+17.6% | $105.2M+5.0% | $100.3M-5.5% | $98.5M-2.2% | |
| Xalabrands | $39.2M+5.7% | $42M+13.2% | $38.6M-6.3% | $40.7M-10.7% | $37.1M-12.7% | |
| Xanax ® | $34.8M+7.7% | $39.5M+8.2% | $34.2M-11.4% | $33.9M-4.2% | $32.3M-6.4% | |
| Yupelri ® | $62.5M+7.2% | $70.6M+6.0% | $71.4M+14.8% | $66.6M+22.2% | $58.3M+5.6% | |
| Zoloft ® | $72.6M+20.6% | $66.8M+14.8% | $66.8M+10.2% | $61.1M+3.7% | $60.2M+3.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Viatris break its business down?
- Viatris (VTRS) reports net sales by business across 4 parts — Developed Markets Segment, Emerging Markets Segment, Greater China and Japan, Australia and New Zealand Segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Viatris's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Viatris's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
